has anyone died from glp-1 Nurse's death linked to weight-loss drug Mounjaro approved on NHS Retatrutide for weight loss: Study

Toledo et al., 2023)

Across much of the South and Midwest, the combination of high obesity prevalence, lower wages, and limited insurance coverage creates what could be described as GLP-1 deserts regions where access is constrained not just by price, but by insurance exclusions and state-level policy decisions

For instance, N-terminally truncated GLP-1 analogs showed a significantly higher loss in binding affinity and potency compared to truncated exendin-4 analogs

Overweight and obesity, in particular, intra-abdominal adiposity, are associated with various cardiometabolic conditions including type 2 diabetes (T2D), dyslipidemia, hypertension, atherosclerotic cardiovascular disease, and heart failure [2, 3]

Weeks 9 through 12: 8mg weekly

Injection site reactions including erythema, pruritus, or mild indurationoccur in some patients, with frequency varying by product (from low single-digit percentages to over 10%)